Y-mAbs Therapeutics, Inc. - Special Call Transcript
(technical difficulty) strategy of Y-mAbs Therapeutics.
Thank you, Sara. Good morning, and welcome to Y-mAbs R&D Day. Unfortunately, it's virtual today, but we are very happy to have it done today.
Let me quickly remind you that the following discussions contain certain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, and the disclaimer is on the screen right now. I'll give you a second.
Okay. So to the big news, the BLA for DANYELZA was approved November 25, and which was a fantastic milestone for Y-mAbs. This -- the first trial was started way back in 2003, so it's a big milestone. And today, we'll learn more about the very encouraging data that -- from the use of DANYELZA in clinic. First, we are pleased to have Dr. Shakeel Modak from the Memorial Sloan Kettering Cancer Center, talk about our HITS
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |